Patents

Patent applications related to ESG increased by 2% per year on average in the pharmaceutical industry since 2020

Credit: Bert van Dijk/Getty images.

Powered by

The global pharmaceutical industry experienced a 2% rise in annual average growth rate (AAGR) in the number of ESG-related patent applications between 2020 and 2022. The total number of ESG-related grants increased by an AAGR of 2% during the same period, according to GlobalData's patent analytics database.  

Notably, the number of ESG-related patent applications in the pharmaceutical industry was 98,905 since 2020, while 54,072 applications were granted.

The top five assignees by filings accounted for 5% of patent applications

Analysis of patent applications by assignee shows that LG filed the most ESG patents within the pharmaceutical industry since 2020. The company filed 918 ESG-related patents since 2020.  

It was followed by E. Merck (618 applications), Chinese Academy of Sciences (609 applications), F. Hoffmann-La Roche (596 applications) and Zhejiang University (550 applications).  

The top five assignees by grants accounted for 8% of successful patent grants

Analysis of patent grants by assignee shows that LG was granted 619 patents related to ESG within the pharmaceutical industry since 2020. It was followed by Chinese Academy of Sciences (574 grants), E. Merck (567 grants), F. Hoffmann-La Roche (405 grants) and Corteva (394 grants).

Patent activity was driven by China with a 43% share of total patent publications

The largest share of ESG-related patent publications in the pharmaceutical industry since 2020 was held by China with 43%, followed by the US (15%) and Japan (7%).

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patents Analytics tracks patent filings and grants from official patent offices around the world. Proprietary analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.

Go to article: Home | Nanoparticle drug delivery research gets a boostGo to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Project UpdatesGo to article: NiproGo to article: In DepthGo to article: Covid-19 vaccine success bolsters nanoparticle drug delivery research Go to article: eConsent in clinical trials: What’s on the horizon?Go to article: Breathing easy: How digital inhalers are changing asthma treatmentGo to article: Primate models in pharma: What the future holds Go to article: A decade on, what’s next for CAR-T therapies?Go to article: FDA’s $7bn plan for 2024: Disclose CMOs, restart Cancer MoonshotGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: Thematic TakeGo to article: Thematic Take: contentsGo to article: ForewordGo to article: ESG is the most important theme of this decadeGo to article: A timeline of corporate ESGGo to article: The most pressing ESG concerns for the pharma industryGo to article: Key trends impacting ESG performance in the healthcare sectorGo to article: Latest news: ESG in pharmaGo to article: Sustainable supply chains: Clinical trials in a new era of limited resourcesGo to article: Increase in DPI use could lead to decreases in greenhouse gas emissionsGo to article: Environmental sustainability innovation: Leading companies in anti-malarial compositionsGo to article: Deal activity related to ESG in the pharmaceutical industry since 2020Go to article: ESG hiring trends in the global pharmaceutical industry since 2020Go to article: ESG patent applications in the global pharmaceutical industry since 2020Go to article: Mentions of ESG in pharmaceutical industry company filings since 2020 Go to article: GlobalData Thematic IntelligenceGo to article: Pharma Sponsored SupplementsGo to article: CfPIEGo to article: ListingsGo to article: EventsGo to article: RankingsGo to article: Buyer's GuidesGo to article: Next issue